#USA #Cambridge #Antibody Discovery #Biointron #RushData

Biointron's Innovative RushData Platform

In a significant advancement for biotechnology, Biointron Biological USA Inc., renowned for its expertise in antibody discovery, has officially introduced RushData. This integrated service platform emerges at a time when the demand for rapid, data-driven antibody discovery is surging, powered by artificial intelligence (AI) and machine learning (ML).

A Game-Changing Solution for Antibody Development

RushData is designed to bridge the gap in traditional antibody research methodologies, which have often been slow and disjointed. Historically, the process of antibody sequence generation to validation could take several weeks—an inconvenient bottleneck for researchers eager to iterate their designs rapidly. With RushData, bio-researchers can transition from submitting antibody sequences to obtaining high-quality experimental data in just days.

This acceleration is made possible by Biointron's proprietary one-day transient CHO (Chinese Hamster Ovary) expression system. CHO cells are highly regarded for their capacity to produce antibodies that possess human-like properties, essential for successful therapeutic development. By employing this system, RushData not only speeds up the process but also enhances the predictive quality of the data collected, aligning perfectly with current AI and ML models that can generate vast numbers of antibody candidates in a single cycle.

Enhanced Workflow Integration

The RushData platform integrates various stages of the antibody discovery workflow into a cohesive unit. It encompasses antibody expression, binding characterization, and developability testing, significantly improving the efficiency of data generation. Furthermore, researchers can analyze interactions and properties simultaneously, facilitating a seamless transition through the design-build-test-learn cycle.

One of the stand-out features of RushData is its capability to handle over 3,000 molecules concurrently. This high-throughput processing not only amplifies data collection but also offers standardized, AI-ready formats suitable for further analysis.

Key Features of the RushData Platform:

• - One-Day Expression: Utilizing CHO cells for rapid antibody screening and iteration.
• - Parallel Processing: Ability to process and analyze 3,000+ molecules in each batch.
• - Comprehensive Binding Characterization: Integrates binding analysis through techniques such as Biolayer Interferometry (BLI) and Surface Plasmon Resonance (SPR).
• - Early Developability Profiling: Offers assessments on thermal stability and self-interaction behavior, enabling early identification of potential issues.

Flexible Service Options Tailored to Researchers

Understanding the diverse needs of researchers, the RushData platform provides multiple service packages:

• - Basic Package: Rapid screening, including expression, titer, and affinity testing.
• - Standard Package: Comprehensive binding characterization alongside expression evaluation.
• - Premium Package: Developability profiling with in-depth binding characterization.

This flexibility is crucial as it accommodates varying stages of antibody discovery, ensuring that researchers can select a package that aligns with their specific requirements.

Biointron's Legacy and Future Aspirations

With more than 14 years of service to over 3,000 biopharma companies globally, Biointron leverages its extensive knowledge in antibody production to expand its platform capabilities continually. The introduction of RushData epitomizes the company's commitment to advancing the frontiers of biologics research.

For additional information on RushData or to explore how Biointron can assist in your antibody discovery needs, visit Biointron's website or contact their team directly at +1 (732) 790-8340.

Biointron, founded in 2012 and certified to ISO 9001:2015 standards, remains at the forefront of antibody discovery, providing invaluable support to biotech and pharmaceutical organizations worldwide. Their approach not only shortens production times but also transforms computational predictions into experimentally validated candidates, thereby revolutionizing the field of biotechnology.